ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "rheumatoid arthritis"

  • Abstract Number: 1242 • ACR Convergence 2021

    Sex Differences in Treatment Response to Three Different Biological Treatments and Corticosteroids in Patients with Early Rheumatoid Arthritis

    Kristina Lend1, Ronald F van Vollenhoven2, Jon Lampa3, Merete Hetland4, Espen Haavardsholm5, Dan Nordström6, Michael Nurmohamed7, Bjorn Gudbjornsson8, Anna Rudin9, Mikkel Ostergaard10, Till Uhlig11, Gerdur Grondal8, Kim Hørslev-Petersen12, Marte S Heiberg5, Tuulikki Sokka-Isler13, Jos Twisk14 and Irene van der Horst-Bruinsma15, 1Department of Medicine, Rheumatology Unit, The Karolinska Institute, Stockholm, Sweden, 2Amsterdam University Medical Centers, Department of Rheumatology and Clinical Immunology, Rheumatology and Immunology Center ARC, Amsterdam, Netherlands, 3Karolinska University Hospital, Department of Medicine, Rheumatology Unit, The Karolinska Institute, Stockholm, Sweden, Stockholm, Sweden, 4DANBIO and COPECARE, Centre for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Denmark, 5Diakonhjemmet Hospital, Oslo, Norway, 6Division of Internal Medicine and Rheumatology, Helsinki University Hospital, Helsinki, Finland, 7Amsterdam University Medical Centers, Amsterdam Rheumatology and Immunology Center, Amsterdam, Netherlands, 8Landspitali University Hospital, University of Iceland, Reykjavik, Iceland, 9Rheumatology Clinic, Sahlgrenska University Hospital, Sahlgrenska Academy of University of Gothenburg, Gothenburg, Sweden, 10Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, and Department of Clinical Medicine, University of Copenhagen, Glostrup, Denmark, 11Diakonhjemmet Hospital, University of Oslo, Oslo, Norway, 12Danish Hospital for Rheumatic Diseases, University of Southern Denmark, Reykjavik, Iceland, Haderslev, Denmark, 13University of Eastern Finland, Jyväskylä Central Hospital, Jyväskylä, Finland, 14Department of Epidemiology and Biostatistics, Amsterdam University Medical Centres, Amsterdam, Netherlands, 15Department of Rheumatology, VU University Medical Centre, Amsterdam, Netherlands

    Background/Purpose: To investigate sex differences in clinical response to three different biological treatments in combination with methotrexate (MTX) versus MTX plus corticosteroids (active conventional treatment;…
  • Abstract Number: 1385 • ACR Convergence 2021

    Overall Survival in Patients with Systemic Autoimmune Diseases Following Lung or Heart-Lung Transplantation at a Single High-Volume Academic Transplant Center: A Comparative Cohort Study

    Jason Melehani1, Shufeng Li2, Joshua Mooney3 and Lorinda Chung2, 1Stanford University, San Jose, CA, 2Stanford University, Palo Alto, CA, 3Stanford University, Stanford, CA

    Background/Purpose: Lung manifestations of systemic autoimmune diseases are a frequent cause of early death. For many patients, current treatments cannot arrest the inexorable progression to…
  • Abstract Number: 1533 • ACR Convergence 2021

    Comparison of Hospitalization and Mortality Rate in Patients with Different Rheumatic Diseases: A Brazilian Registry Cross-Sectional Analysis

    Claudia Marques1, Ana Paula Reis2, Adriana Kakehasi3, Edgard Neto4, Marcelo Medeiros Pinheiro5, Gecilmara Salviato Pileggi6, Gilda Ferreira7, Licia Maria Henrique Mota8, Odirlei Andre Monticielo9, Sandra Lúcia Ribeiro10, Felipe Omura11, Adriana Marinho12, Francinne Ribeiro13, Laurindo Rocha Jr14, Ana Silvia Martins15, Michel Yazbek16, Mariana Souza17, Nathália Sacilotto18, Samuel Shinjo19, Lilian Valadares20, Ana Silva21, Danielle Christine de Brito22, Viviane de Souza23, Carolina Costa24, Samia Studart25, Antônio Ximenes26 and Ricardo Xavier27, 1Hospital das Clnicas - Universidade Federal de Pernambuco - UFPE, Recife, Brazil, 2Centro Universitrio de Braslia- UniCEUB, Brasilia, Brazil, 3Federal University of Minas Gerais, Belo Horizonte, Brazil, 4UNIFESP, São Paulo, Brazil, 5Universidade Federal de São Paulo, São Paulo, Brazil, 6FACISB, Ribeirao Preto, Brazil, 7Federal University of Minas Gerais, Belo Horizonte, Brazil, 8Universidade de Brasília, Brasilia, Brazil, 9Serviço de Reumatologia do Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, 10Universidade Federal do Amazonas, Amazonas, Brazil, 11Clinica Omura, São Paulo, Brazil, 12FUNDHACRE, Rio Branco, Brazil, 13UERJ, Rio de Janeiro, Brazil, 14Instituto de Medicina Integral Professor Fernando Figueira - IMIP, Recife, Brazil, 15UFU, Uberlandia, MG, Brazil, 16UNICAMP, Campinas, Brazil, 17SCBH, Belo Horizonte, Brazil, 18Instituto de Assistência Médica ao Servidor Público Estadual, São Paulo, Brazil, 19Hospital das Clinicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, 20HOSPITAL GETULIO VARGAS, Recife, Brazil, 21UFG, GOIANIA, Goias, Brazil, 22UFPB, Joao Pessoa, Brazil, 23UFJF, JUIZ DE FORA, Brazil, 24UFES, Vitoria, Brazil, 25HOSPITAL GERAL DE FORTALEZA, Fortaleza, Brazil, 26CLINICA CIP, Goiania, Brazil, 27Departamento de Reumatologia, Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil

    Background/Purpose: The COVID-19 pandemic has brought uncertainties to the rheumatological practice, and despite the large number of publications to date, many questions remain unanswered. One…
  • Abstract Number: 1657 • ACR Convergence 2021

    Comprehensive Assessment of Multimorbidity Burden in a Population-based Cohort of Patients with Rheumatoid Arthritis

    Cynthia Crowson1, Tina Gunderson2, Elena Myasoedova2, Elizabeth Atkinson2, Vanessa Kronzer2, Caitrin Coffey2 and John Davis2, 1Mayo Clinic, Eyota, MN, 2Mayo Clinic, Rochester, MN

    Background/Purpose: Multimorbidity is common in patients with rheumatoid arthritis (RA), and it is associated with poor outcomes. The literature on multimorbidity suffers from numerous definitions…
  • Abstract Number: 1673 • ACR Convergence 2021

    Riding Multiple Waves of Uncertainty: Real World Canadian RA Patient Outcomes over 1 Year of COVID-19 Restrictions

    Orit Schieir1, Susan Bartlett2, Marie-France Valois2, Louis Bessette3, Gilles Boire4, Glen Hazlewood5, Carol Hitchon6, Edward Keystone7, Janet Pope8, Diane Tin9, Carter Thorne10, Vivian Bykerk11 and CATCH Investigators12, 1Canadian Early Arthritis Cohort Study, Montréal, QC, Canada, 2McGill University, Montréal, QC, Canada, 3Centre de l'Ostoporose et de Rhumatologie de Qubec, Québec City, QC, Canada, 4Universite de Sherbrooke, Sherbrooke, QC, Canada, 5University of Calgary, Calgary, AB, Canada, 6University of Manitoba, Winnipeg, MB, Canada, 7Keystone Consulting Enterprises Inc., Toronto, ON, Canada, 8University of Western Ontario, London, ON, Canada, 9The Arthritis Program Research Group, Newmarket, ON, Canada, 10Southlake Regional Health Centre, Newmarket, ON, Canada, 11Hospital for Special Surgery, New York, NY, 12Mt Sinai Hospital, Toronto, ON, Canada

    Background/Purpose: During the COVID-19 pandemic, Canadians adults with RA faced considerable uncertainty due to greater risk of infection, hospitalization, changing access to RA medications, and…
  • Abstract Number: 1689 • ACR Convergence 2021

    Safety, Tolerability, Pharmacokinetics, Receptor Occupancy, and Suppression of T-cell-Dependent Antibody Response in a Phase 1 Study with KPL-404, an anti-CD40 Monoclonal Antibody

    Manoj Samant1, Alistair Wheeler2, Guang-Liang Jiang1, Moses Njenga1, Madeline Spiers1, Arian Pano1 and John F Paolini1, 1Kiniksa Pharmaceuticals Corp., Lexington, MA, 2Kiniksa Pharmaceuticals, Ltd., Hamilton, Bermuda

    Background/Purpose: T-cell priming and T-cell-dependent B-cell responses require an intact cluster of differentiation (CD)40/CD40L pathway. CD40 is expressed on the surface of B-cells, dendritic cells,…
  • Abstract Number: 1706 • ACR Convergence 2021

    Twenty-four-week Follow-up of a Randomized Controlled First-in-Human Trial of the Safety and Efficacy of Neurostimulation with a Miniaturized Vagus Nerve Stimulation Device in Patients with Multidrug-Refractory Rheumatoid Arthritis

    Norman Gaylis1, Mark Genovese2, David Sikes3, Alan Kivitz4, Diane Horowitz5, Charles Peterfy6, Yaakov Levine7 and David Chernoff8, 1Arthritis and Rheumatic Disease Specialties, Aventura, FL, 2Stanford University, Sunnyvale, CA, 3Florida Medical Clinic, Wesley Chapel, FL, 4Altoona Center for Clinical Research, Duncansville, PA, 5Northwell Health, Jericho, NY, 6Spire Sciences, Inc., Boca Raton, FL, 7SetPoint Medical, Manhassest, NY, 8SetPoint Medical, Sausalito, CA

    Background/Purpose: Vagus nerve stimulation (VNS) activates innate neuroimmune reflexes that have been shown to reduce pro-inflammatory cytokines and clinical disease activity in subjects with rheumatoid…
  • Abstract Number: 1917 • ACR Convergence 2021

    Sputum TGF-β1 Is Elevated in Subclinical and Clinically Significant Rheumatoid Arthritis-Associated Interstitial Lung Disease and Correlates with Soluble IL-6R Levels

    Timothy Wilson1, Kevin Deane2, Joyce Lee1, Christopher Collora3, Marie Feser3, Mariana Kaplan4, Joshua Solomon5 and Kristen Demoruelle6, 1University of Colorado, Denver, CO, 2University of Colorado Denver, Denver, CO, 3University of Colorado Denver, Aurora, CO, 4National Institutes of Health, Bethesda, MD, 5National Jewish Health, Denver, CO, 6University of Colorado Anschutz Medical Campus, Aurora, CO

    Background/Purpose: Increased levels of transforming growth factor β1 (TGF-β1) in the lung have been implicated in the pathogenesis of several fibrotic lung diseases, but their…
  • Abstract Number: 0019 • ACR Convergence 2021

    Increased Circulating CD39+FoxP3+CD4+ Treg Cells in Early Rheumatoid Arthritis Facilitate the Antiinflammatory Action of Methotrexate

    Laura Nuño1, Alejandro Villalba1, Marta Novella-Navarro2, Irene Monjo1, Diana Peitado1, Sara Garcia-Carazo1, Alejandro Balsa2 and Maria-Eugenia Miranda-Carus1, 1Hospital La Paz - IdiPAZ, Madrid, Spain, 2Immuno-Rheumatology Research Group, Hospital La Paz Institute for Health Research-IdiPAZ, Rheumatology, La Paz University Hospital, Madrid, Spain

    Background/Purpose: Inhibition of AICAR transformylase by MTX results in augmented release of adenine nucleotides to the extracellular space; these are rapidly hydrolysed by ectonucleotidases CD39…
  • Abstract Number: 0036 • ACR Convergence 2021

    The NAD+ Metabolism Is Altered in Rheumatoid Arthritis and Its Modulation with NAD+ Boosters Exhibits Key Anti-Inflammatory and Anti-Oxidant Effects

    Carlos Pérez-Sánchez1, Luz Marina Sanchez-Mendoza2, Nuria Barbarroja3, M.Carmen Abalos-Aguilera4, Maria Luque-Tevar5, Alejandra Patiño-Trives5, Iván Arias de la Rosa3, Cristobal Román-Rodriguez6, Juan Antonio Moreno2, Maria Isabel Buron2, Jose Antonio Gonzalez-Reyes2, Marta Rojas-Gimenez4, Eduardo Collantes-Estevez6, alejandro Escudero6, Jose Manuel Villalba2 and Chary lopez-pedrera6, 1IMIBIC, Córdoba, Spain, 2Department of Cell Biology, Physiology and Immunology, University of Córdoba, Campus de Excelencia Internacional Agroalimentario, ceiA3, Cordoba, Spain, 3University of Cordoba/IMIBIC/Reina Sofia Hospital, Cordoba, Spain, 4Rheumatology service, IMIBIC/Reina Sofia Hospital/University of Córdoba, Cordoba, Spain, 5Rheumatology Department, Reina Sofia University Hospital/ Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ University of Cordoba, Cordoba, Spain, 6IMIBIC/Reina Sofia Hospital/University of Córdoba, Córdoba, Spain

    Background/Purpose: NAD+ is a key cofactor and second messenger for multiple cellular processes that exhibits antioxidant, anti-apoptotic, and anti-inflammatory properties. Numerous publications and clinical trials…
  • Abstract Number: 0103 • ACR Convergence 2021

    Patients with Inflammatory Rheumatic Diseases Are at Increased Risk of COVID-19 Related Hospitalization: Data from a Prospective Controlled Cohort Study

    Laura Boekel1, Femke Hooijberg1, Erik Vogelzang2, Maureen Leeuw1, Sadaf Atiqi1, Ronald van Vollenhoven3, Alexandre Voskuyl2, Irene van der Horst-Bruinsma2, Willem Lems1, Taco Kuijpers2, Marieke van Ham4, Luuk Wieske2, Filip Eftimov2, Maurice Steenhuis4, Sofie Keijzer4, Olvi Christianawati4, Floris Loeff4, Sander Tas5, Mike Nurmohamed6, Theo Rispens4 and Gertjan Wolbink1, 1Reade, Amsterdam, Netherlands, 2Amsterdam UMC, Amsterdam, Netherlands, 3Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Center, Amsterdam Rheumatology Center, Amsterdam, Netherlands, 4Sanquin, Amsterdam, Netherlands, 5Amsterdam UMC, locatie AMC, Utrecht, Netherlands, 6Reade; Amsterdam Rheumatology & Immunology Center, Amsterdam, Netherlands

    Background/Purpose: Retrospective studies have suggested that patients with rheumatic diseases may be at increased risk of severe COVID-19 related disease, and that this risk may…
  • Abstract Number: 0178 • ACR Convergence 2021

    Abdominal Obesity May Confound Accuracy of Cardiovascular Risk Prediction in Rheumatoid Arthritis; Can Coronary Atherosclerosis Imaging and Biomarkers Help?

    George Karpouzas1, sarah ormseth2, Elizabeth Hernandez2 and Matthew Budoff3, 1Harbor-UCLA Medical Center, Torrance, CA, 2The Lundquist Institute, Harbor-UCLA Medical Center, Torrance, CA, 3Division of Cardiology, and the Lundquist Institute ay Harbor-UCLA Medical Center, Torrance, CA

    Background/Purpose: Accurate cardiovascular risk stratification is essential in rheumatoid arthritis (RA) care. Previous studies evaluated the impact of obesity (defined as body mass index) on…
  • Abstract Number: 0275 • ACR Convergence 2021

    Impact of Disease Activity on Left Ventricular Diastolic Dysfunction in Rheumatoid Arthritis Patients

    Natalia Guajardo-Jauregui, Dionicio Galarza-Delgado, Iris Colunga-Pedraza, Jose Azpiri-Lopez, Alejandra Rodriguez-Romero, Alejandro Meza-Garza, Julieta Loya-Acosta, Jesus Cardenas-de La Garza, Salvador Lugo-Perez, Catalina Andrade-Vazquez and Alan De Leon-Yañez, Hospital Universitario "Dr Jose E. Gonzalez", Monterrey, Mexico

    Background/Purpose: Cardiovascular disease (CVD) is the main cause of mortality in patients with rheumatoid arthritis (RA) reflected by a higher prevalence of cardiovascular risk factors…
  • Abstract Number: 0293 • ACR Convergence 2021

    Increased Prevalence of Scleroderma Specific Autoantibodies in Seropositive Rheumatoid Arthritis with Lung Involvement

    Vasiliki Koulouri1, Kyriaki Tavernaraki2, Mayra Giannelou3 and Clio Mavragani1, 1National and Kapodistrian University of Athens, Athens, Greece, 2Imaging and Interventional Radiology, Sotiria General and Chest Diseases Hospital, Athens, Greece, 3Department of Rheumatology, General Hospital of Athens "G. Gennimatas", Athens, Greece

    Background/Purpose: To evaluate the prevalence of scleroderma (SSc) specific and anti-Ro52 autoantibodies in seropositive rheumatoid arthritis (RA) patients with lung involvement.Methods: Sera from 67 seropositive…
  • Abstract Number: 0494 • ACR Convergence 2021

    The Distribution of Social Deprivation, Distance to Care and Disease Burden in Rheumatoid Arthritis Patients in the United States

    Sharon Dowell1, Huifeng Yun2, Jeffrey Curtis3, Lang Chen4, Manuela Pedra-Nobre5, Dianne Wollaston6, SAWSAN NAJMEY7, Cynthia Lawrence-Elliott8, Theresa Lawrence-Ford9, Heather North10, Robin Dore11, Soha Dolatabadi12, Thaila Ramanujam13, Anne Winkler14, Stacy Kennedy15, Stephanie Ott16, Stephanie Ledbetter17, Grace Wright18 and Gail Kerr19, 1Howard University College of Medicine, Washington, DC, 2University of Alabama Birmingham, Birmingham, AL, 3Division of Clinical Immunology and Rheumatology, Department of Medicine, Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, 4University of Alabama, Birmingham, AL, 5North Jersey Rheum. Center, Westfield, NJ, 6Memorial Advanced Rheumatology, Houston, TX, 7Midstate Rheumatology Center, PA, Freehold, NJ, 8North Georgia Rheum Group, Atlanta, GA, 9North Georgia Rheum Group, Atlanta, MD, 10Pardee UNC, Hendersonville, NC, 11Robin K. Dore, MD Inc, Tustin, CA, 12Soha Dolatabadi, MD, Los Angeles, CA, 13Santa Cruz Rheumatology, Inc., Santa Cruz, CA, 14Winkler Medical Practice, Springfield, MO, 15Rowan Diagnostic Clinic, Concord, NC, 16Fairfield Medical Center, Carroll, OH, 17University of Alabama at Birmingham, Birmingham, AL, 18Grace C Wright MD PC, and Association of Women in Rheumatology, New York, NY, 19Washington D.C., Veterans Affairs Medical Center (VAMC)/Georgetown and Howard Universities, Washington, DC

    Background/Purpose: The overall success of RA therapy is dependent on access to specialty care, insurance coverage and effective management of associated comorbidities. Whether RA disease…
  • « Previous Page
  • 1
  • …
  • 108
  • 109
  • 110
  • 111
  • 112
  • …
  • 188
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology